ClinicalTrials.gg
RecruitingNCT06313944GE-R-A-TPSUpdated Oct 13, 2026

German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation

An observational study in Alzheimer Disease, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 6 sites in Germany. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Heinrich-Heine University, Duesseldorf · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 13, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Alzheimer Disease with a site in Germany — 26 open to participants now, 39 under way, 17 of them phase 3. Alzheimer Disease · Germany.

Planned enrollment
14th of 20
100 · median 170
Started
2025
with 13 others
Observational
20 of 213
7 open now
Primary completion
2027-10
later than 17 of 38 live
Registered
186th of 213
by date

Among the 213 studies in Alzheimer Disease with a site in Germany, this one is the 14th largest by planned enrollment of the 20 observational ones that give a count, is one of 14 that started in 2025, is one of 20 observational ones, reaches primary completion later than 17 of the 38 other live ones, and was the 186th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

26 of the 213 studies in Alzheimer Disease with a site in Germany are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Alzheimer Disease with a site in Germany, or all of them as a file.
02

Study summary

This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores.

Read the detailed description

This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores. Adverse effects and adverse events without a clear causal relationship will be documented in terms of frequency and severity. Furthermore, the progression of improvement in Alzheimer's symptoms as a result of TPS treatment is summarized in various neuropsychological scales.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer Disease
  • Transcranial Pulse Wave Stimulation (TPS)
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

AD Patients undergoing TPS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

i. Age = 18 to 85 ii. N>=100, clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the as a screening tool) and impairment of activities of daily living for more than six months iii. MRI scan, in vivo evidence from CSF and/or PET using the NIA-AA criteria, which categorize the underlying pathological processes based on biomarkers, should be added if possible, but are optional. These biomarkers are categorized as ß-amyloid deposition, pathological tau and neurodegeneration [AT(N)], which can be detected on imaging and in biofluids. If possible, patients with Alzheimer's disease (AD) or Alzheimer's continuum should be included.

iv. TPS treatment in a center of a neurological or psychiatric specialist and performed under supervision of a specialist

Exclusion criteria

Exclusion Criteria:

i. Relevant intracerebral pathologies not related to Alzheimer's disease, such as vascular encephalopathy Fazekas grade 3, tumors, vascular malformations, pregnancy, metal implants, CAA according to Boston criteria, Z.n. or during antibody therapy ii. Blood coagulation disorders or oral anticoagulation iii. Epilepsy iv. Medical conditions leading to non-compliance with the protocol

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Clinical Alzheimer's syndrome treated with TPS

    Patients with clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months that have planned treatment with TPS

    Diagnostic Test: Registry

Interventions

  • Diagnostic testRegistry

    Clinical data collection of patients scheduled for on-label treatment

06

What researchers measure

Primary outcomes

  1. Number of (Serious) Adverse Events

    Number of adverse events (without causal relationship to therapy) AE, SAE (query after the first 6-cycle block and before each booster) scaling according to NRS (1-10) for each ADE (query before each stimulation)

    Time frame: through study completion, an average of 1 year

  2. Number of adverse device effects

    Number of ADEs and (U)SADEs scaling according to NRS (1-10) for each ADE (query before each stimulation)

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. ADAS

    Alzheimer's Disease Asessment Scale (ADAS) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)

    Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months

  2. Mini Mental State Examination (MMSE) baseline and follow- up

    Mini Mental State Examination (MMSE) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)

    Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months

  3. BDI-II

    BDI-II baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)

    Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months

  4. Clinical Dementia Rating Sum of Boxes Score (CDR-SB)

    Clinical Dementia Rating Sum of Boxes Score (CDR-SB) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)

    Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months

  5. Alzheimer's Disease Cooperative Study/ Activities of Daily Living Scale (ADCS-ADL)

    Alzheimer's Disease Cooperative Study/ Activities of Daily Living Scale (ADCS-ADL) at baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)

    Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months

Other outcomes

  1. Numeric Rating Scale (NRS) for the main symptom

    Numeric Rating Scale (NRS) for the main symptom

    Time frame: 12 months

07

Study locations

4 of 6 sites recruiting
  • Ernst von Bergmann Klinikum - Klinik für Neurologie und Klinische Neuropsychologie
    Potsdam, Brandenburg 14467, Germany
    Recruiting
  • Evangelische Krankenhausstiftung Oldenburg - Universitätsklinik für Neurologie
    Oldenburg, Lower Saxony 26122, Germany
    Recruiting
  • Universitätsklinikum Bonn - Klinik für Parkinson, Schlaf- und Bewegungsstörungen
    Bonn, North Rhine-Westphalia 53127, Germany
    Not yet recruiting
  • Neurologische Praxis Prof. Wojtecki
    Neuss, North Rhine-Westphalia 41460, Germany
    Recruiting
  • Hospital zum Heiligen Geist GmbH & Co KG Klinik für Neurologie und Neurorehabilitation
    Kempen, 47906, Germany
    Withdrawn

    Not enrolling at this site.

  • Praxis Dr. Schwarz
    Ulm, 89073, Germany
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2027, 25 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 25 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 15, 2024
StartActual
Aug 6, 2025
Primary completionEst.
Oct 1, 2027was Oct 2026
CompletionEst.
Oct 1, 2027was Oct 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Neurologische Praxis Prof. Wojtecki is now Recruiting
Oct 13, 2026
Primary completion
Oct 1, 2026→Oct 1, 2027
Oct 13, 2026
Study completion
Oct 1, 2026→Oct 1, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Neurologische Praxis Prof. Wojtecki is now Recruiting
    Primary completion Oct 1, 2026→Oct 1, 2027
    Study completion Oct 1, 2026→Oct 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06313944
Collaborators
Storz Medical AG
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Aug 6, 2025
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Lars Wojtecki, Prof. Dr.
Contact
wojtecki@uni-duesseldorf.de
+492118106756
Lars Wojtecki, Prof. Dr.
principal investigator · Heinrich-Heine-Universität

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion